Phase 3 N=43 Anidulafungin In Treatment Of Candidemia In Asian Subjects
Candidemia
Primary: Number of Subjects With Global Response of Success at End of Treatment — 31 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=224 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
Bipolar Disorder
Primary: Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score — -12.6; -14.3; -6.8 units on a scale — p=<0.001
Phase 3 N=2,322 Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
Chemotherapy-Induced Nausea and Vomiting (CINV)
Primary: A Complete Response (no Vomiting and no Use of Rescue Therapy) Overall (in the 120 Hours Following Initiation of Cisplatin). — 795; 820 Participants
Phase 3 N=1,166 Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
Diphtheria · Tetanus · Haemophilus Infection
Primary: Percentage of Participants With 4-fold Rises in Levels of Pentacel™ Vaccine Antibody Titers Post-dose 3 When Given at Different Times or Concurrently With a Pneumococcal…
Phase 3 N=843 Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001
Phase 3 N=248 Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -49.45; -34.43 percent change — p=<0.01
Phase 3 N=135 Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
Crohn's Disease
Primary: Number of Subjects Without Mucosal Ulceration at Week 12 — 8; 17 Subjects — p=0.056
Phase 3 N=317 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
Type 2 Diabetes Mellitus
Primary: Change From Baseline (i.e., Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54 — -2.37; -1.86 Percent HbA1c
Phase 3 N=1,027 V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥255 mIU/mL — 395; 203 Participants
Phase 3 N=480 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL for Subjects Initially…
Phase 3 N=109 Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
Post-Stroke Spasticity · Cerebrovascular Accident
Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups…
Phase 3 N=39 Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis
Multiple Sclerosis
Primary: Difference Between the Number of Newly Active Lesions in Magnetic Resonance Imaging (MRI) Per Three Months During the 6-month Treatment Period and the Number of Newly…
Phase 3 N=2,388 Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients
Seasonal Allergic Rhinitis
Primary: Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS) — -25.10; -18.17; -26.35; -21.21 Percent change of TNSS from baseline
Phase 3 N=74 A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction
Cholestasis, Extrahepatic
Primary: Adequate Clinical Palliation of the Biliary Obstruction — 54 participants
Phase 3 N=3,927 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL — 726; 718; 736; 772…